Abstract
Thioredoxin (Trx) expression is increased in several human primary cancers and the Trx/Trx reductase (TrxR) system therefore provides an attractive target for cancer drug development. Novel organotellurium antioxidants, especially a primitive analog of vitamin E (compound 1d) and compounds 7, 9 and 10 - all carrying highly functionalized 4-(dialkylamino)phenyltelluro groups to secure high antioxidative capacity - were found to inhibit TrxR with IC50 values in the low micromolar range. Whereas antioxidant 1d also inhibited the growth of MCF-7 human breast cancer cells in culture at a similar level (IC50 = 1.8 μM), the other TrxR inhibitors were inactive in concentrations below about 10 μM.
Original language | English (US) |
---|---|
Pages (from-to) | 153-161 |
Number of pages | 9 |
Journal | Anti-cancer drugs |
Volume | 14 |
Issue number | 2 |
DOIs | |
State | Published - Feb 2003 |
Keywords
- Antioxidant
- Antitumor activity
- Organotellurium compound
- Thioredoxin reductase
ASJC Scopus subject areas
- Oncology
- Pharmacology
- Pharmacology (medical)
- Cancer Research